Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 + Gemcitabine in BCG-Failure NMIBC
NCT01625260Phase 2Terminated
- Sponsor
- Altor BioScience Corporation
- Start
- Mar 2012
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pemvidutide in non-muscle-invasive bladder cancer (NMIBC), sponsored by Altor BioScience Corporation. Started Mar 2012; status: terminated.
02
Drugs
pemvidutide
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT01625260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625260.